NCT05429905 2023-03-09
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
KK Women's and Children's Hospital
Phase 1/2 Unknown
Clinical Trials
1 trialsPhase 1/2 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Clinical Trials, Phase I as Topic × Clear all